StreetInsider.com News Articles

Viking Therapeutic (VKTX) PT Lowered to $106 at Canaccord

Tue, 20 Oct 2026 06:45:04 -0400

(Updated - October 20, 2026 6:45 AM EDT)

Canaccord analyst Edward Nash lowered the price target on Viking Therapeutic (NASDAQ: VKTX) to $106.00 (from $114.00) while maintaining a Buy rating.

The analyst commented: "This morning, we are publishing a note on evolving pricing dynamics in the obesity space. In that note, we detail an ongoing shift away from high WAC pricing characteristic of the biotech industry towards lower prices dominated by cash pay programs and MFN pricing agreements with the White House. We believe reduced pricing is largely offset by a growing overall market size, leaving room for continued revenue growth. This

Viking Therapeutic (VKTX) PT Lowered to $106 at Canaccord

Tue, 20 Oct 2026 06:45:04 -0400

(Updated - October 20, 2026 6:45 AM EDT)

Canaccord analyst Edward Nash lowered the price target on Viking Therapeutic (NASDAQ: VKTX) to $106.00 (from $114.00) while maintaining a Buy rating.

UBS Starts Viking Therapeutic (VKTX) at Buy

Wed, 14 Oct 2026 16:32:50 -0400

UBS analyst Joon Lee initiates coverage on Viking Therapeutic (NASDAQ: VKTX) with a Buy rating and a price target of $94.00.

For an analyst ratings summary and ratings history on Viking Therapeutic click here. For more ratings news on Viking Therapeutic click here.

Shares of Viking Therapeutic closed at $26.65 yesterday.

UBS Starts Viking Therapeutic (VKTX) at Buy

Wed, 14 Oct 2026 16:32:50 -0400

UBS analyst Joon Lee initiates coverage on Viking Therapeutic (NASDAQ: VKTX) with a Buy rating and a price target of $94.00.

For an analyst ratings summary and ratings history on Viking Therapeutic click here. For more ratings news on Viking Therapeutic click here.

Shares of Viking Therapeutic closed at $26.65 yesterday.

Viking Therapeutics starts Phase 3 trials for oral obesity drug VK2735

Wed, 14 Oct 2026 07:05:17 -0400

Viking Therapeutics, Inc. (NASDAQ: VKTX) has initiated two Phase 3 clinical trials, SUNRISE-1 and SUNRISE-2, to evaluate an oral formulation of its dual GLP-1/GIP receptor agonist VK2735 in adults with obesity, according to a company press release.

Each study is a randomized, double-blind, placebo-controlled, multicenter trial targeting enrollment of 560 adults. SUNRISE-1 will enroll obese or overweight adults without type 2 diabetes who have at least one weight-related comorbidity, while SUNRISE-2 will enroll obese or overweight adults with type 2 diabetes. Participants will receive once-daily oral VK2735 at doses of 27.5 mg, 35 mg, or 55 mg, or placebo, for 68

Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity

Wed, 14 Oct 2026 07:05:00 -0400

SUNRISE -1 and SUNRISE-2 Studies to Evaluate Oral VK2735 in Obese Adults with and without Type 2 Diabetes

SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of the SUNRISE Phase 3 clinical program for

Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity

Wed, 14 Oct 2026 07:05:00 -0400

SUNRISE -1 and SUNRISE-2 Studies to Evaluate Oral VK2735 in Obese Adults with and without Type 2 Diabetes

Viking Therapeutic (VKTX) PT Lowered to $85 at Truist Securities

Wed, 07 Oct 2026 07:14:41 -0400

Truist Securities analyst Gregory Renza lowered the price target on Viking Therapeutic (NASDAQ: VKTX) to $85.00 (from $87.00) while maintaining a Buy rating.

Viking Therapeutics starts oral VK2735 maintenance dosing trial

Tue, 06 Oct 2026 07:06:34 -0400

Viking Therapeutics, Inc. (NASDAQ: VKTX) has initiated Part 2 of an exploratory maintenance dosing study for VK2735, its dual GLP-1/GIP receptor agonist, according to a company statement.

The randomized, double-blind, placebo-controlled trial will enroll approximately 195 adults with obesity, defined as a body mass index of 30 kg/m² or higher. Participants will first receive weekly subcutaneous doses of VK2735 or placebo for 21 weeks. After that period, they will transition to one of several maintenance regimens: daily oral doses, weekly oral doses, monthly subcutaneous doses, every-other-week subcutaneous doses, or placebo. The study will run through Week 33, with exploratory endpoints measuring

Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity

Tue, 06 Oct 2026 07:05:00 -0400

Study to Explore Oral Maintenance Dosing Regimens Following Initial Weight Loss with Subcutaneous VK2735

Monthly and Every-Other-Week Subcutaneous Regimens to also be Evaluated

SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the

Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity

Tue, 06 Oct 2026 07:05:00 -0400

Study to Explore Oral Maintenance Dosing Regimens Following Initial Weight Loss with Subcutaneous VK2735

Monthly and Every-Other-Week Subcutaneous Regimens to also be Evaluated

SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the

Form 8-K Viking Therapeutics, For: Sep 23

Mon, 28 Sep 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20260928/27115620.html

Viking Therapeutics raises $575M through stock and note offerings

Mon, 28 Sep 2026 16:30:22 -0400

Viking Therapeutics, Inc. (Nasdaq: VKTX) closed concurrent public offerings of common stock and convertible senior notes, raising approximately $575.0 million in gross proceeds, according to a press release dated Sept. 28, 2026.

The company sold 9,035,714 shares of common stock at $35.00 per share and $258.75 million in aggregate principal amount of 2.00% convertible senior notes due 2032. The totals included the full exercise by underwriters of options to purchase an additional 1,178,571 shares of common stock and an additional $33.75 million in notes.

After deducting underwriting discounts, commissions, and estimated offering expenses, Viking estimates net proceeds of approximately $547.8 million.

The company

Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Co

Mon, 28 Sep 2026 16:30:00 -0400

Gross Proceeds to Viking Approximately $575 Million

SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the closing of its concurrent upsized public offerings of 9,035,714 shares of common stock, at a public offering price of $35.00 per

Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Co

Mon, 28 Sep 2026 16:30:00 -0400

Gross Proceeds to Viking Approximately $575 Million

Form 424B5 Viking Therapeutics,

Fri, 25 Sep 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260925/27103757.html

Form 424B5 Viking Therapeutics,

Fri, 25 Sep 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260925/27103758.html

One investor reportedly took a third of Viking’s share sale

Thu, 24 Sep 2026 14:04:41 -0400

Investing.com -- Viking Therapeutics Inc. completed a $500 million capital raise through a two-part offering, with one investor acquiring approximately one-third of the shares in the upsized equity portion, Bloomberg reported Thursday.

The obesity drug developer raised $275 million through a stock offering and an additional $225 million from the sale of six-year convertible bonds, according to a company statement.

The stock offering drew demand for several times the available shares after being increased in size, according to people familiar with the matter who requested anonymity. More than 75% of the offering was allocated to 10 investors, the people said.

Viking Therapeutics shares

Viking share sale investor said to be allocated a third of deal -Bloomberg

Thu, 24 Sep 2026 13:11:58 -0400

Viking share sale investor said to be allocated a third of deal -Bloomberg

Viking Therapeutics prices $500M stock and convertible notes offering

Thu, 24 Sep 2026 07:05:17 -0400

Viking Therapeutics, Inc. (Nasdaq: VKTX) priced two concurrent public offerings totaling approximately $500 million, the company announced Sept. 24, 2026.

The clinical-stage biopharmaceutical company priced 7,857,143 shares of common stock at $35.00 per share, and $225.0 million in aggregate principal amount of 2.00% convertible senior notes due 2032. Both offerings were increased from an initially announced size of $200.0 million each. Settlement is scheduled for Sept. 25, 2026, subject to customary closing conditions.

Underwriters were granted a 30-day option to purchase up to an additional 1,178,571 shares of common stock and up to an additional $33.75 million in notes to cover over-allotments.

Viking Therapeutics prices $500M stock and convertible notes offering

Thu, 24 Sep 2026 07:05:17 -0400

Viking Therapeutics, Inc. (Nasdaq: VKTX) priced two concurrent public offerings totaling approximately $500 million, the company announced Sept. 24, 2026.

Underwriters were granted a 30-day option to purchase up to an additional 1,178,571 shares of common stock and up to an additional $33.75 million in notes to cover over-allotments.

Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes

Thu, 24 Sep 2026 07:05:00 -0400

SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its concurrent public offerings of 7,857,143 shares of common stock, at a public offering price of $35.00 per share, and $225.0 million aggregate principal amount of 2.00% convertible senior notes due 2032 (the "notes"). The offering size of each of the common

Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes

Thu, 24 Sep 2026 07:05:00 -0400

Form FWP Viking Therapeutics, Filed by: Viking Therapeutics, Inc.

Thu, 24 Sep 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20260924/27098477.html

Form 305B2 Viking Therapeutics,

Thu, 24 Sep 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260924/27098406.html